Journal Mobile Options
Table of Contents
Vol. 41, No. 1, 2008
Issue release date: November 2007
Psychopathology 2008;41:10–16
(DOI:10.1159/000109950)

‘Mental Retardation’ or ‘Intellectual Disability’: Time for a Conceptual Change

Salvador-Carulla L. · Bertelli M.
WPA Section ‘Psychiatry of Mental Retardation/Intellectual Disability’, Jerez, Spain

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: The term ‘mental retardation’ (MR) is outdated and has changed to ‘intellectual disability’ (ID). Unfortunately, this decision did not follow a nosology approach. The aim of this overview is twofold: (1) to provide a conceptual background and framing on the ID/MR field to other psychiatrists, and (2) to provide a nosology-based perspective to the debate on the name and concept of MR/ID. Method: This conceptual paper is based on a literature review and on an iterative process of debate within the WPA Section ‘Psychiatry of Mental Retardation’. Results: ID may be regarded not as a disease or as a disability but as a syndrome grouping (metasyndrome) similar to the construct of dementia. It includes a heterogeneous group of clinical conditions, ranging from genetic to nutritional, infectious, metabolic or neurotoxic conditions. The ID metasyndrome is characterized by a deficit in cognitive functioning prior to the acquisition of skills through learning. The intensity of the deficit is such to interfere in a significant way with individual normal functioning as expressed in limitations in activities and restriction in participation (disabilities). Conclusions: The name ‘developmental cognitive impairment’ is here suggested to coexist with ID for naming the metasyndrome previously called MR following a polysemic-polynomious approach.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Durkin M: The epidemiology of developmental disabilities in low-income countries. Ment Retard Dev Disabil Res Rev 2002;8:206–211.
  2. Salvador-Carulla L, Rodríguez-Blázquez C, Rodríguez de Molina M, Pérez-Marín J, Velázquez R: Hidden psychiatric morbidity in a vocational programme for people with intellectual disability. J Intellect Disabil Res 2000;44:147–154.
  3. Polder JJ, Meerding WJ, Bonneux L, van der Maas PJ: Healthcare costs of intellectual disability in the Netherlands: a cost-of-illness perspective. J Intellect Disabil Res 2002;46:168–178.
  4. Centers for Disease Control and Prevention (CDC): Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment – United States, 2003. MMWR Morb Mortal Wkly Rep 2004;53:57–59.

    External Resources

  5. Nyhan WL: Lesch-Nyhan Disease. J Hist Neurosci 2005;14:1–10.
  6. Eliez S, Blasey CM, Schmitt EJ, White CD, Hu D, Reiss AL: Velocardiofacial syndrome: are structural changes in the temporal and mesial temporal regions related to schizophrenia? Am J Psychiatry 2001;158:447–453.
  7. Murray CJL, Lopez AD (eds): The Global Burden of Disease and Injury Series. Cambridge, Harvard University Press, 1996, vol 1: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020.
  8. American Association on Mental Retardation (AAMR): Ad hoc Committee on Terminology and Classification. AAMR News Notes 2001;14:10–13.
  9. Schalock RL: What’s in a name? Ment Retard 2002;40:59–61.
  10. Turnbull R, Turnbull A, Warren S, Marchand P: Shakespeare redux, or Romeo and Juliet revisited: embedding a terminology and name change in a new agenda for the field of mental retardation. Ment Retard 2002;40:65–70.
  11. Berrios G: Aspectos históricos y conceptuales; in Salvador L (ed): Retraso mental y enfermedad psiquiátrica: evaluación, tratamiento y servicios. Barcelona, Ediciones en Neurociencias, 1995, pp 1–22.
  12. World Health Organization: International Classification of Functioning, Disability and Health (ICF). Geneva, World Health Organization, 2001.
  13. American Association on Mental Retardation (AAMR): Mental Retardation: Definition, Classification and System of Supports, ed 10. Washington, American Association on Mental Retardation, 2002.
  14. UK Department of Health: Valuing People. London, Department of Health, 2001.
  15. Thompson PM, Cannon TD, Narr KL, van Erp T, Poutanen VP, Huttunen M, Lonnqvist J, Standertskjold-Nordenstam CG, Kaprio J, Khaledy M, Dail R, Zoumalan CI, Toga AW: Genetic influences on brain structure. Nat Neurosci 2001;4:1153–1154.
  16. Gardner H: Intelligence Reframed. New York, Basic Books, 1999.
  17. Flynn JR: IQ gains, WISC subtests, and fluid g: g theory and the relevance of Spearman’s hypothesis to race; in Bock GR, Goode JA (eds): The Nature of Intelligence. New York, Wiley, 2000.
  18. Martorell-Cafranga A, Ayuso-Mateos JL: Uncertainty on the measurement of intelligence. Actas Esp Psiquiatr 2004;32:98–106.
  19. Kaufman AS: Intelligence Testing with the WISC-III. New York, Wiley, 1994.
  20. Salvador-Carulla L, Novell Alsina R: Guía Práctica de la Evaluación Psiquiátrica en el Retraso Mental. Barcelona, Aula Médica, 2002.
  21. Smith JD: The myth of mental retardation: paradigm shifts, disaggregation, and developmental disabilities. Ment Retard 2002;40:62–64.
  22. Gelb SA: The dignity of humanity is not a scientific construct. Ment Retard 2002;40:55–56.
  23. Boteva K, Lieberman J: Reconsidering the classification of schizophrenia and manic depressive illness – A critical analysis and new conceptual model. World J Biol Psychiatry 2003;4:81–92.
  24. IGDA Workgroup, WPA: IGDA 1: Conceptual bases – Historical, cultural and clinical perspectives. Br J Psychiatry Suppl 2003;45:s40–s41.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50